Juventas Therapeutics, Inc. Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development
1/28/2013 9:54:34 AM
More...
|
Juventas Therapeutics, Inc. Doses First Patient in Phase II STOP-HF Trial
8/20/2012 10:52:31 AM
More...
|
Juventas Therapeutics, Inc. Raises $22.2 Million Series B Financing
7/16/2012 8:04:06 AM
More...
|
Juventas Therapeutics, Inc. Enrolling Patients in Phase IIa STOP-CLI Clinical Trial
5/15/2012 12:29:27 PM
More...
|
BioCardia and Juventas Therapeutics, Inc. Announce Phase II Development Program of JVS-100 Delivered With the Helical Infusion System to Treat Heart Failure
3/15/2012 6:20:34 AM
More...
|
Juventas Therapeutics, Inc. Reports One Year Data From Phase I Heart Failure Clinical Trial
1/30/2012 11:04:22 AM
More...
|
Wound Care Technologies to Acquire Medical Device Distributor Juventas Therapeutics, Inc.; Bryant Gaines Named WNDM COO Effective Immediately
12/1/2011 10:03:33 AM
More...
|
Juventas Therapeutics, Inc. Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
5/25/2011 8:23:01 AM
More...
|
Juventas Therapeutics, Inc. Completes Successful Phase I Clinical Trial for JVS-100 in Treatment of Patients with Heart Failure; Looks to Raise $25 Million in Series B
4/26/2011 8:01:49 AM
More...
|
Juventas Therapeutics, Inc. Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia
1/3/2011 7:47:25 AM
More...
|
|